Biolinq has created a new Biowearable experience by using an array of electrochemical sensors so small you can barely feel them. Our metabolic health sensors work together to provide maximum reliability for continuous sensing applications. With the potential of multiple analytes such as glucose, ketones, and lactate, we provide an entirely new user experience with actionable metabolic health insights. Over the next 10 years we intend to bring Biosensing and Biowearables mainstream. We are dedicated to the personal and professional growth of all our team members and strive to create a positive and creative work environment.
$58M sweet spot round size
$58M
from 2 investors over 1 rounds
Biolinq raised $58M on May 4, 2024
Investors: Alpha Wave Ventures and + 8 Other investors